4.3 Review

An effective drug against COVID-19: reality or dream?

Journal

EXPERT REVIEW OF RESPIRATORY MEDICINE
Volume 15, Issue 4, Pages 505-518

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/17476348.2021.1854092

Keywords

SARS-CoV-2; covid-19; pneumonia; clinical trials; drug

Ask authors/readers for more resources

This study provides a comprehensive overview of the current literature on effective anti-SARS-CoV-2 drugs, highlighting the lack of specific drugs for COVID-19 treatment, but promising therapeutic potential in drugs like remdesivir and favipiravir currently undergoing initial clinical studies.
Introduction: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is well known as a novel member of the coronavirus family which caused a sudden outbreak of Coronavirus disease-2019 (COVID-19) in China that quickly developed into a global pandemic. No effective approaches are found as yet for the therapy and epidemiological control of this new virus. We searched the literature in PubMed, Scopus, Web of Knowledge, Google Scholar, and MeSH, for articles and abstracts describing SARS-CoV-2, COVID-19, pneumonia, clinical trials, drug, treatment, and medicine. Areas covered: The present study aimed to comprehensively overview the current literature on effective anti-SARS-CoV-2 drugs. Expert opinion: Since the beginning of this pandemic disease, many studies have been conducted to find effective drugs to prevent COVID-19, because there are no specific drugs for the treatment of this disease. Most of these drugs with the antiviral potential effect toward COVID-19 are already used as the treatment of other infectious diseases. Some drugs that show the promising therapeutic potential in the initial clinical studies include remdesivir as an inhibitor of RNA-dependent RNA polymerase and favipiravir as an inhibitor of virus replication. Currently, remdesivir received the FDA authorizes to use as an experimental drug for emergency use in COVID-19 patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available